Advertisement

Picture EBD Group BIO-Europe 2020 Digital Event BEU2020 650x81
Organisation › Details

WuXi Biologics (2269.HK)

WuXi Biologics (stock code: 2269.HK), a Hong Kong-listed company, is a leading global open-access biologics technology platform offering end-to-end solutions to empower organizations to discover, develop and manufacture biologics from concept to commercial manufacturing. Our company history and achievements demonstrate our commitment to providing a truly ONE-stop service offering and strong value proposition to our global clients. As of June 30, 2019, there were a total of 224 integrated projects, including 106 projects in pre-clinical development stage, 102 projects in early-phase (phase I and II) clinical development, 15 projects in late-phase (phase III) development and one project in commercial manufacturing. With total estimated capacity for biopharmaceutical production planned in China, Ireland, Singapore, and the U.S. exceeding 280,000 liters by 2022, we will provide our biomanufacturing partners with a robust and premier-quality global supply chain network. *

 

Period Start 2015-01-01 reorganised (incorp)
  Group WuXi PharmaTech (Group)
Products Industry biopharmaceutical production technology
  Industry 2 contract manufacturing (biologicals)
Person Person Chen, Zhisheng (Chris) (WuXi Pharmatech 201812 CEO of WuXi Biologics)
     
Region Region Wuxi
  Country China
  Street 108 Meiliang Road. W
MaShan Binhu District
  City 214092 Wuxi City
    Address record changed: 2020-01-12
     
Basic data Employees n. a.
     
    * Document for �About Section�: Almirall S.A.. (1/9/20). "Press Release: Almirall and WuXi Biologics Sign Strategic Collaboration Agreement for Multiple Bispecific Antibodies Targeting Dermatology Diseases". Barcelona.
     
   
Record changed: 2020-01-12

Advertisement

Picture EBD Group BIO-Europe 2020 Digital Event BEU2020 650x81

More documents for WuXi PharmaTech (Group)


To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to info@iito.de and simply fill the subject line with the word »LSE Newsletter«

To get even more information, please take a look at our [gs] professional services offering and read the gene-sensor Product Flyer [PDF file]

Advertisement

Picture [iito] No Content Marketing 650x80px




» top